Drugplain

AZACTAM 2 g/1

AZTREONAM · INJECTION, POWDER, FOR SOLUTION · E.R. Squibb & Sons, L.L.C.

1 Recall on Record
Plain English

AZACTAM is a injection, powder, for solution containing aztreonam at 2 g/1, taken intramuscular. Manufactured by E.R. Squibb & Sons, L.L.C..

Key Facts

Brand Name
AZACTAM
Generic Name
AZTREONAM
NDC Code (Product)
0003-2570
Manufacturer
E.R. Squibb & Sons, L.L.C.
Strength
2 g/1
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAMUSCULAR, INTRAVENOUS
Marketing Status
Application #
NDA050580
Drug Class
Monobactam Antibacterial [EPC]
Marketing Start
04/01/2010

Recall History

1 Recall on Record
Class II09/18/2015

Sentara Enterprises

Lack of Assurance of Sterility: Product sterility cannot be guaranteed.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

off label use190 reports
pyrexia170 reports
eosinophilia154 reports
drug ineffective147 reports
rash129 reports
dyspnoea125 reports
acute kidney injury121 reports
drug reaction with eosinophilia and systemic symptoms113 reports
thrombocytopenia106 reports
septic shock100 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis

Dosage & Administration

DOSAGE AND ADMINISTRATION Dosage in Adult Patients AZACTAM may be administered intravenously or by intramuscular injection. Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient. Table 2: AZACTAM Dosage Guidelines for Adults* * Maximum recommended dose is 8 g per day. Type of Infection Dose Frequency (hours) Urinary tract infections 500 mg or 1 g 8 or 12 Moderately severe systemic infections 1 g or 2 g 8 or 12 Severe systemic or life-threatening infections 2 g 6 or 8 Because of the serious nature of infections due to Pseudomonas aeruginosa , dosage of 2 g every six or eight hours is recommended, at least upon initiation of therapy, in systemic infections caused by this organism. The intravenous route is recommended for patients requiring single doses greater than 1 g or those with bacterial septicemia, localized parenchymal abscess (eg, intra-abdominal abscess), peritonitis, or other severe systemic or life-threatening infections. The duration of therapy depends on the severity of infection. Generally, AZACTAM should be continued for at least 48 hours after the patient b

Warnings

WARNINGS Both animal and human data suggest that AZACTAM (aztreonam for injection, USP) is rarely cross-reactive with other beta-lactam antibiotics and weakly immunogenic. Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure. (See CONTRAINDICATIONS .) Careful inquiry should be made to determine whether the patient has any history of hypersensitivity reactions to any allergens. While cross-reactivity of aztreonam with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams (eg, penicillins, cephalosporins, and/or carbapenems). Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure to aztreonam. If an allergic reaction to aztreonam occurs, discontinue the drug and institute supportive treatment as appropriate (eg, maintenance of ventilation, pressor amines, antihistamines, corticosteroids). Serious hypersensitivity reactions may require epinephrine and other emergency measures. (See ADVERSE REACTIONS .) Clostridium difficile –associated diarrhea (CDAD) has been reported with use of

Contraindications

CONTRAINDICATIONS This preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

Adverse Reactions

ADVERSE REACTIONS Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively. Systemic reactions (considered to be related to therapy or of uncertain etiology) occurring at an incidence of 1% to 1.3% include diarrhea, nausea and/or vomiting, and rash. Reactions occurring at an incidence of less than 1% are listed within each body system in order of decreasing severity: Hypersensitivity —anaphylaxis, angioedema, bronchospasm Hematologic —pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis Gastrointestinal —abdominal cramps; rare cases of C. difficile –associated diarrhea, including pseudomembranous colitis, or gastrointestinal bleeding have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (See WARNINGS .) Dermatologic —toxic epidermal necrolysis (see WARNINGS ), purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis Cardiovascular —hypotension, transient ECG changes

Frequently Asked Questions

What is AZACTAM used for?

AZACTAM contains AZTREONAM. It is a injection, powder, for solution taken intramuscular. Consult your doctor for specific uses.

Is AZACTAM a controlled substance?

AZACTAM is not classified as a controlled substance by the DEA.

What is the generic name for AZACTAM?

The generic name for AZACTAM is AZTREONAM. There are 6 other brand versions of AZTREONAM.

What is the NDC code for AZACTAM 2 g/1?

The NDC (National Drug Code) for AZACTAM 2 g/1 is 0003-2570, listed by E.R. Squibb & Sons, L.L.C..

Product NDC

0003-2570

Package NDC

0003-2570-16

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)